Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Boosted by Canvas Wealth Advisors LLC

Canvas Wealth Advisors LLC increased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 431.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,158 shares of the medical equipment provider's stock after acquiring an additional 13,119 shares during the quarter. Canvas Wealth Advisors LLC's holdings in Hologic were worth $940,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HOLX. Geode Capital Management LLC increased its holdings in Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after purchasing an additional 144,838 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after buying an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock valued at $322,272,000 after acquiring an additional 129,035 shares in the last quarter. Invesco Ltd. raised its holdings in Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after acquiring an additional 572,187 shares in the last quarter. Finally, Boston Partners boosted its stake in Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on HOLX shares. Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Morgan Stanley decreased their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Evercore ISI dropped their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $77.42.

Insider Activity at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Stock Performance

Shares of HOLX stock traded up $0.24 during trading hours on Monday, reaching $65.25. The stock had a trading volume of 1,000,240 shares, compared to its average volume of 2,366,779. The firm has a market capitalization of $14.54 billion, a PE ratio of 27.53, a price-to-earnings-growth ratio of 2.38 and a beta of 0.55. The firm has a 50-day simple moving average of $60.00 and a 200-day simple moving average of $63.90. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. Hologic's revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.03 earnings per share. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.